Overview

A Two-Part Infant Study for Early Diagnosis of Respiratory Syncytial Virus (RSV) and Evaluation of JNJ-53718678 in RSV Acute Respiratory Tract Disease

Status:
Completed
Trial end date:
2021-05-15
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this two-part designed study is to assess in the setting of a planned early interception of pediatric RSV disease, early viral and disease kinetics (observational stage) and the antiviral effects of an Respiratory Syncytial Virus (RSV) fusion inhibitor, JNJ-53718678 (interventional stage). In the observational stage the infant is closely monitored for early symptoms by the parent(s)/caregiver(s) and thus may be brought in for diagnosis earlier than in the typical setting.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Janssen Research & Development, LLC
Criteria
Inclusion Criteria:

Part 1: Observational Stage

- The infant is less than or equal to (<=) 4 months of age at enrollment and
asymptomatic for acute respiratory illness (ARI)-like symptoms requiring medical
intervention at the time of consent to participate in the study

- At least 1 parent/caregiver must be able to use the respiratory syncytial virus (RSV)
mobile application (App) at home via his/her own Android/iOS electronic device
(compatible with RSV mobile App)

- The participant must have been assessed per local public health practice and
considered not to have Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection

Part 2: Interventional Stage

- The infant is 28 days and if prematurely born infant (that is [i.e.], less than [<] 37
weeks and 0 days of gestation at birth) is at least 3 months postnatal age

- The participant has been diagnosed with RSV infection using a rapid molecular-based
diagnostic assay

- The participant weighs more than 2.4 kilogram (kg)

- The participant has an acute respiratory illness as evaluated by the investigator

- Except for the RSV-related illness, the participant must be medically stable in case
of allowed co-morbid conditions

- The participant must have been assessed per local public health practice and
considered not to have SARS-CoV-2 infection during this respiratory infection

Exclusion Criteria:

Part 1: Observational Stage

- The participant has any physical abnormality which limits the ability to collect
regular nasal specimens

- The participant is receiving chronic home oxygen therapy at enrollment (applicable to
both parts)

Part 2: Interventional Stage

- The participant is <3 months postnatal age at screening and was born prematurely
(i.e., <37 weeks and 0 days of gestation) or if the participant weights <2.4 kg

- The participant has a QT interval with Fridericia's correction (QTcF) greater than (>)
450 milliseconds per the machine read (mean of triplicate) parameter result confirmed
by repeat triplicate Electrocardiogram (ECG) recording during screening

- The participant is considered by the investigator to be immunocompromised, whether due
to underlying medical condition or medical therapy

- The participant has had any of: a) Confirmed SARS-CoV-2 infection (test positive)
during the four weeks prior to randomization, or b) Close contact with a person with
Coronavirus Disease 2019 (COVID-19) (test confirmed or suspected SARS-CoV-2 infection)
within 14 days prior to randomization